AR016264A1 - Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha - Google Patents

Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha

Info

Publication number
AR016264A1
AR016264A1 ARP990102133A ARP990102133A AR016264A1 AR 016264 A1 AR016264 A1 AR 016264A1 AR P990102133 A ARP990102133 A AR P990102133A AR P990102133 A ARP990102133 A AR P990102133A AR 016264 A1 AR016264 A1 AR 016264A1
Authority
AR
Argentina
Prior art keywords
cell
expression
gene
endogeno
ifna2
Prior art date
Application number
ARP990102133A
Other languages
English (en)
Original Assignee
Docampo Palacios Maite L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Docampo Palacios Maite L filed Critical Docampo Palacios Maite L
Publication of AR016264A1 publication Critical patent/AR016264A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una construccion de ADN que altera la expresion de un gen endogeno de IFNA2 en células de mamífero al integrarse al genoma de la célula por mediode recombinacion homologa; que comprende: (i) una secuencia objetivo que contiene al menos 20nucleotidos contiguos de una o más de SEQ ID NO.: 7, 8, 12, 16,17, 18 y 19; y (ii) una secuencia reguladora de la transcripcion; célula homologamente recombinante, método para alterar la expresion del gen endogenode IFNA2 en una célula de mamífero,uso de dicha célula para la manufactura de un medicamento, método para producir IFNA2 y molécula de ácido nucleicoaislado.
ARP990102133A 1998-05-07 1999-05-06 Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha AR016264A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8464898P 1998-05-07 1998-05-07
US8655598P 1998-05-21 1998-05-21

Publications (1)

Publication Number Publication Date
AR016264A1 true AR016264A1 (es) 2001-06-20

Family

ID=26771248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102133A AR016264A1 (es) 1998-05-07 1999-05-06 Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha

Country Status (14)

Country Link
EP (1) EP1075531A1 (es)
JP (1) JP2002513580A (es)
KR (1) KR20010052278A (es)
CN (1) CN1309710A (es)
AR (1) AR016264A1 (es)
AU (1) AU3788899A (es)
CA (1) CA2328459A1 (es)
CZ (1) CZ299418B6 (es)
HU (1) HUP0102517A3 (es)
IL (1) IL139433A0 (es)
NO (1) NO20005585L (es)
PL (1) PL344517A1 (es)
TR (1) TR200003271T2 (es)
WO (1) WO1999057292A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
WO2012139195A1 (en) * 2011-04-13 2012-10-18 National Research Council Of Canada EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNα2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery

Also Published As

Publication number Publication date
CZ20003705A3 (cs) 2001-04-11
CN1309710A (zh) 2001-08-22
JP2002513580A (ja) 2002-05-14
NO20005585D0 (no) 2000-11-06
CA2328459A1 (en) 1999-11-11
WO1999057292A1 (en) 1999-11-11
TR200003271T2 (tr) 2001-03-21
PL344517A1 (en) 2001-11-05
HUP0102517A2 (hu) 2001-11-28
EP1075531A1 (en) 2001-02-14
KR20010052278A (ko) 2001-06-25
AU3788899A (en) 1999-11-23
CZ299418B6 (cs) 2008-07-16
WO1999057292A9 (en) 1999-12-16
NO20005585L (no) 2001-01-05
IL139433A0 (en) 2001-11-25
HUP0102517A3 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
CN115651927B (zh) 编辑rna的方法和组合物
US5908779A (en) Targeted RNA degradation using nuclear antisense RNA
CN113286880A (zh) 调控基因组的方法和组合物
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
AR005568A1 (es) Moleculas y construcciones de adn para aumentar la expresion de genes foraneos; celulas y plantas transformadas y metodo para producirlas
KR20220004674A (ko) Rna를 편집하기 위한 방법 및 조성물
CN105316337A (zh) 嗜热链球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
CN105316324A (zh) 嗜热链球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
AR003112A1 (es) Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas
CN105331608A (zh) 脑膜炎双球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
CN105331607A (zh) 嗜热链球菌CRISPR-Cas9系统识别的人CCR5基因的靶序列和sgRNA及其应用
CN105331609A (zh) 脑膜炎双球菌CRISPR-Cas9系统识别的人CCR5基因的靶序列和sgRNA及其应用
GB2617658A (en) Class II, type V CRISPR systems
WO2002014495B1 (en) Enhanced homologous recombination mediated by lambda recombination proteins
KR20110128345A (ko) 생물학적 활성 ｒｎａ의 전달을 위한 조성물 및 방법
SE9901298D0 (sv) Xylose isomerase with improved kinetic properties
ES2066759T3 (es) Regulador antisentido de la expresion de un gen en celulas de plantas.
ATE362989T1 (de) Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren
AR016263A1 (es) Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio
AR016262A1 (es) Una construccion de adn que altera la expresion de un gen pshbeta endogeno, una celula homologamente recombinante, un metodo para alterar la expresion dela fshbeta endogeno en la celula de un mamifero, uso de dicha celula para la manufactura de un medicamento, un metodo para producir fshbeta y una m
RU2012130149A (ru) Векторная система на основе aslv
AR016264A1 (es) Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha
US20230383253A1 (en) Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy
US20230374456A1 (en) T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy
EP1728859A4 (en) SEQUENCE CAPABLE OF ACCELERATING GENE EXPRESSION AT A MODERATELY LOW TEMPERATURE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal